Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Subscribe To Our Newsletter & Stay Updated